Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02161783 · ClinicalTrials.gov registry record
Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation
A clinical trial of Primary Graft Failure and Secondary Graft Failure, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT02161783 is a study of Primary Graft Failure and Secondary Graft Failure that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02161783, a study of Primary Graft Failure and Secondary Graft Failure, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a guideline for the treatment of graft failure after hematopoietic stem cell transplant (HSCT). This regimen, consisting of cyclophosphamide and fludarabine with low dose total body irradiation (TBI) is designed to promote donor engraftment by day 42 after initial graft failure. The graft will consist of bone marrow or G-CSF mobilized peripheral blood from a haploidentical related donor. The source of stem cells will be determined by the transplant team based on factors such as patient's age, medical history, donor availability and will be according to the current University of Minnesota Blood and Marrow Transplantation Program selection guidelines.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- RADIATION Total Body Irradiation
- BIOLOGICAL Hematopoietic stem cell infusion
Study Locations (1)
Minnesota
- University of Minnesota Medical Center, Fairview - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-10-06 |
| Est. Completion | 2032-01-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02161783
The ClinicalTrials.gov registry entry for NCT02161783 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Primary Graft Failure appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT02161783 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02161783 about?
NCT02161783 is a clinical study titled "Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation". This is a guideline for the treatment of graft failure after hematopoietic stem cell transplant (HSCT). This regimen, consisting of cyclophosphamide and fludarabine with low dose total body irradiation (TBI) is designed to promote donor engraftment by day 42 after initial graft failure. The graft w...
What is the current status of trial NCT02161783?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2014-10-06. Estimated completion is 2032-01-30.
What conditions does trial NCT02161783 study?
This clinical trial studies the following conditions: Primary Graft Failure, Secondary Graft Failure.
What interventions are being tested in trial NCT02161783?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Total Body Irradiation (RADIATION), Hematopoietic stem cell infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT02161783?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02161783 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Graft Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.